Aurobindo Pharma Ltd · AUROPHARMA · Pharma - Formulators · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 5 November 2026
Aurobindo Pharma share price today: ₹1,796.30 at the close on 18 November 2026, up 49.0% in a year. Aurobindo Pharma (AUROPHARMA) is worth ₹1,03,367 crore, trades at a P/E of 26.0 and has closed between ₹1,132.50 and ₹1,823.20 over the past 52 weeks. Latest change: revenue up on a year earlier for 13 quarters in a row (every quarter we can compare).
Aurobindo Pharma Ltd's share price has risen faster than its earnings: +49.0% in a year, against +17.0% for earnings per share.
The main question: the share price moved +49.0% in a year while earnings per share (last four quarters) moved +17.0%. The difference came from the market paying a higher multiple.
The price has been rising for 49 weeks, and the P/E is higher than 97% of its own last 11 years. Over the last four quarters, results have been improving, with profit +32.5% on a year earlier, and 117% of the last 3 years' profit came in as cash. What will decide it: whether earnings grow into a price that has already moved.
What is the Aurobindo Pharma share price today?
Aurobindo Pharma Ltd's share price was ₹1,796.30 at the close on 18 November 2026. It has been rising for 49 weeks. That is 18.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,133 and ₹1,823, and at that close it sat 96% of the way up from that low.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Aurobindo Pharma Ltd is in stage 2. The phase helps read everything below.
Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 47 weeks in a row.
Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 248 of 554 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 11 Mar 2016 | no NIFTY 500 reading |
| 18 Mar 2016 | no NIFTY 500 reading |
| 23 Mar 2016 | no NIFTY 500 reading |
| 1 Apr 2016 | no NIFTY 500 reading |
| 8 Apr 2016 | no NIFTY 500 reading |
| 13 Apr 2016 | no NIFTY 500 reading |
| 22 Apr 2016 | no NIFTY 500 reading |
| 29 Apr 2016 | no NIFTY 500 reading |
| 6 May 2016 | no NIFTY 500 reading |
| 13 May 2016 | no NIFTY 500 reading |
| 20 May 2016 | no NIFTY 500 reading |
| 27 May 2016 | no NIFTY 500 reading |
| 3 Jun 2016 | no NIFTY 500 reading |
| 10 Jun 2016 | −7.7% |
| 17 Jun 2016 | −7.3% |
| 24 Jun 2016 | −12.3% |
| 1 Jul 2016 | −6.8% |
| 8 Jul 2016 | −8.2% |
| 15 Jul 2016 | −12.4% |
| 22 Jul 2016 | −6.6% |
| 29 Jul 2016 | −7.1% |
| 5 Aug 2016 | −16.9% |
| 12 Aug 2016 | −16.3% |
| 19 Aug 2016 | −14.2% |
| 26 Aug 2016 | −4.4% |
| 2 Sep 2016 | −10.9% |
| 9 Sep 2016 | −2.9% |
| 16 Sep 2016 | −1.5% |
| 23 Sep 2016 | +8.5% |
| 30 Sep 2016 | +9.4% |
| 7 Oct 2016 | +2.9% |
| 14 Oct 2016 | +4.7% |
| 21 Oct 2016 | −1.3% |
| 30 Oct 2016 | +1.1% |
| 4 Nov 2016 | −4.2% |
| 11 Nov 2016 | +6.3% |
| 18 Nov 2016 | +1.0% |
| 25 Nov 2016 | −1.1% |
| 2 Dec 2016 | −0.3% |
| 9 Dec 2016 | −3.5% |
| 16 Dec 2016 | −5.2% |
| 23 Dec 2016 | −13.2% |
| 30 Dec 2016 | −16.2% |
| 6 Jan 2017 | −13.2% |
| 13 Jan 2017 | −11.6% |
| 20 Jan 2017 | −10.7% |
| 27 Jan 2017 | −12.2% |
| 3 Feb 2017 | −10.0% |
| 10 Feb 2017 | −19.1% |
| 17 Feb 2017 | −18.6% |
| 23 Feb 2017 | −21.1% |
| 3 Mar 2017 | −17.0% |
| 10 Mar 2017 | −18.4% |
| 17 Mar 2017 | −14.2% |
| 24 Mar 2017 | −9.6% |
| 31 Mar 2017 | −13.6% |
| 7 Apr 2017 | −18.5% |
| 13 Apr 2017 | −17.9% |
| 21 Apr 2017 | −21.2% |
| 28 Apr 2017 | −25.2% |
| 5 May 2017 | −22.2% |
| 12 May 2017 | −16.9% |
| 19 May 2017 | −18.6% |
| 26 May 2017 | −27.9% |
| 2 Jun 2017 | −21.3% |
| 9 Jun 2017 | −16.3% |
| 16 Jun 2017 | −11.0% |
| 23 Jun 2017 | −8.1% |
| 30 Jun 2017 | −2.8% |
| 7 Jul 2017 | +0.5% |
| 14 Jul 2017 | +6.0% |
| 21 Jul 2017 | +10.6% |
| 28 Jul 2017 | +12.8% |
| 4 Aug 2017 | +16.0% |
| 11 Aug 2017 | +11.5% |
| 18 Aug 2017 | +14.3% |
| 24 Aug 2017 | +34.2% |
| 1 Sep 2017 | +23.7% |
| 8 Sep 2017 | +17.9% |
| 15 Sep 2017 | +10.3% |
| 22 Sep 2017 | +3.1% |
| 29 Sep 2017 | −2.2% |
| 6 Oct 2017 | +3.4% |
| 13 Oct 2017 | −3.6% |
| 19 Oct 2017 | −2.3% |
| 27 Oct 2017 | +1.2% |
| 3 Nov 2017 | +3.1% |
| 10 Nov 2017 | −3.7% |
| 17 Nov 2017 | −5.7% |
| 24 Nov 2017 | −9.8% |
| 1 Dec 2017 | −14.8% |
| 8 Dec 2017 | −14.0% |
| 15 Dec 2017 | −15.7% |
| 22 Dec 2017 | −13.9% |
| 29 Dec 2017 | −10.9% |
| 5 Jan 2018 | −19.0% |
| 12 Jan 2018 | −18.7% |
| 19 Jan 2018 | −23.5% |
| 25 Jan 2018 | −23.8% |
| 2 Feb 2018 | −24.8% |
| 9 Feb 2018 | −21.4% |
| 16 Feb 2018 | −17.9% |
| 23 Feb 2018 | −15.9% |
| 1 Mar 2018 | −9.0% |
| 9 Mar 2018 | −9.7% |
| 16 Mar 2018 | −11.9% |
| 23 Mar 2018 | −12.3% |
| 28 Mar 2018 | −12.8% |
| 6 Apr 2018 | −3.5% |
| 13 Apr 2018 | −2.7% |
| 20 Apr 2018 | +0.0% |
| 27 Apr 2018 | +2.3% |
| 4 May 2018 | +1.9% |
| 11 May 2018 | +1.9% |
| 18 May 2018 | −1.4% |
| 25 May 2018 | −0.9% |
| 1 Jun 2018 | −14.6% |
| 8 Jun 2018 | −7.1% |
| 15 Jun 2018 | +3.4% |
| 22 Jun 2018 | +5.1% |
| 29 Jun 2018 | +6.0% |
| 6 Jul 2018 | −0.5% |
| 13 Jul 2018 | −4.0% |
| 20 Jul 2018 | −5.0% |
| 27 Jul 2018 | −7.7% |
| 3 Aug 2018 | −2.0% |
| 10 Aug 2018 | −3.3% |
| 17 Aug 2018 | +7.1% |
| 24 Aug 2018 | +9.8% |
| 31 Aug 2018 | +25.2% |
| 7 Sep 2018 | +33.9% |
| 14 Sep 2018 | +25.5% |
| 21 Sep 2018 | +23.4% |
| 28 Sep 2018 | +23.1% |
| 5 Oct 2018 | +26.7% |
| 12 Oct 2018 | +28.4% |
| 19 Oct 2018 | +35.3% |
| 26 Oct 2018 | +33.9% |
| 2 Nov 2018 | +33.5% |
| 9 Nov 2018 | +41.5% |
| 16 Nov 2018 | +27.3% |
| 22 Nov 2018 | +23.8% |
| 30 Nov 2018 | +22.6% |
| 7 Dec 2018 | +3.3% |
| 14 Dec 2018 | −2.0% |
| 21 Dec 2018 | −1.9% |
| 28 Dec 2018 | −3.2% |
| 4 Jan 2019 | −7.5% |
| 11 Jan 2019 | +0.9% |
| 18 Jan 2019 | −3.0% |
| 25 Jan 2019 | +2.4% |
| 1 Feb 2019 | +0.3% |
| 8 Feb 2019 | −7.7% |
| 15 Feb 2019 | −5.8% |
| 22 Feb 2019 | −7.9% |
| 1 Mar 2019 | −9.8% |
| 8 Mar 2019 | −5.1% |
| 15 Mar 2019 | +1.8% |
| 22 Mar 2019 | +2.0% |
| 29 Mar 2019 | +2.7% |
| 5 Apr 2019 | +1.4% |
| 12 Apr 2019 | −5.4% |
| 18 Apr 2019 | −4.0% |
| 26 Apr 2019 | −2.0% |
| 3 May 2019 | −8.6% |
| 10 May 2019 | −4.5% |
| 17 May 2019 | −12.9% |
| 24 May 2019 | −15.9% |
| 31 May 2019 | −15.7% |
| 7 Jun 2019 | −21.5% |
| 14 Jun 2019 | −21.8% |
| 21 Jun 2019 | −22.4% |
| 28 Jun 2019 | −22.4% |
| 5 Jul 2019 | −23.8% |
| 12 Jul 2019 | −21.1% |
| 19 Jul 2019 | −25.6% |
| 26 Jul 2019 | −27.1% |
| 2 Aug 2019 | −22.5% |
| 9 Aug 2019 | −17.3% |
| 16 Aug 2019 | −6.5% |
| 23 Aug 2019 | −2.5% |
| 30 Aug 2019 | −2.2% |
| 6 Sep 2019 | +8.4% |
| 13 Sep 2019 | +8.4% |
| 20 Sep 2019 | +6.4% |
| 27 Sep 2019 | +0.9% |
| 4 Oct 2019 | +0.9% |
| 11 Oct 2019 | −23.2% |
| 18 Oct 2019 | −15.6% |
| 27 Oct 2019 | −19.0% |
| 1 Nov 2019 | −20.9% |
| 8 Nov 2019 | −33.6% |
| 15 Nov 2019 | −39.4% |
| 22 Nov 2019 | −38.4% |
| 29 Nov 2019 | −34.4% |
| 6 Dec 2019 | −36.4% |
| 13 Dec 2019 | −36.7% |
| 20 Dec 2019 | −31.3% |
| 27 Dec 2019 | −27.9% |
| 3 Jan 2020 | −28.2% |
| 10 Jan 2020 | −4.6% |
| 17 Jan 2020 | −4.8% |
| 24 Jan 2020 | −0.5% |
| 1 Feb 2020 | −4.3% |
| 7 Feb 2020 | +21.0% |
| 14 Feb 2020 | +22.3% |
| 20 Feb 2020 | +37.0% |
| 28 Feb 2020 | +18.2% |
| 6 Mar 2020 | +20.8% |
| 13 Mar 2020 | +9.0% |
| 20 Mar 2020 | +1.4% |
| 27 Mar 2020 | +14.0% |
| 3 Apr 2020 | +16.3% |
| 9 Apr 2020 | +25.9% |
| 17 Apr 2020 | +36.4% |
| 24 Apr 2020 | +50.3% |
| 30 Apr 2020 | +52.6% |
| 8 May 2020 | +43.9% |
| 15 May 2020 | +53.9% |
| 22 May 2020 | +47.4% |
| 29 May 2020 | +62.8% |
| 5 Jun 2020 | +54.2% |
| 12 Jun 2020 | +85.5% |
| 19 Jun 2020 | +108.6% |
| 26 Jun 2020 | +76.7% |
| 3 Jul 2020 | +72.4% |
| 10 Jul 2020 | +59.9% |
| 17 Jul 2020 | +37.3% |
| 24 Jul 2020 | +8.6% |
| 31 Jul 2020 | +27.0% |
| 7 Aug 2020 | +17.1% |
| 14 Aug 2020 | +9.4% |
| 21 Aug 2020 | −9.9% |
| 28 Aug 2020 | −6.7% |
| 4 Sep 2020 | −4.5% |
| 11 Sep 2020 | −11.2% |
| 18 Sep 2020 | −8.1% |
| 25 Sep 2020 | −8.0% |
| 1 Oct 2020 | −3.6% |
| 9 Oct 2020 | −8.9% |
| 16 Oct 2020 | −11.8% |
| 23 Oct 2020 | −11.1% |
| 30 Oct 2020 | −17.7% |
| 6 Nov 2020 | −23.0% |
| 14 Nov 2020 | −15.8% |
| 20 Nov 2020 | −14.7% |
| 27 Nov 2020 | −11.2% |
| 4 Dec 2020 | −5.5% |
| 11 Dec 2020 | −6.5% |
| 18 Dec 2020 | −11.8% |
| 24 Dec 2020 | −6.0% |
| 1 Jan 2021 | −9.0% |
| 8 Jan 2021 | −9.0% |
| 15 Jan 2021 | −7.9% |
| 22 Jan 2021 | −3.2% |
| 29 Jan 2021 | −0.8% |
| 5 Feb 2021 | −1.5% |
| 12 Feb 2021 | −11.3% |
| 19 Feb 2021 | −11.2% |
| 26 Feb 2021 | −15.2% |
| 5 Mar 2021 | −18.4% |
| 12 Mar 2021 | −18.2% |
| 19 Mar 2021 | −15.6% |
| 26 Mar 2021 | −13.8% |
| 1 Apr 2021 | −12.8% |
| 9 Apr 2021 | −5.2% |
| 16 Apr 2021 | −1.3% |
| 23 Apr 2021 | +5.4% |
| 30 Apr 2021 | −1.0% |
| 7 May 2021 | +5.1% |
| 14 May 2021 | +8.5% |
| 21 May 2021 | +10.2% |
| 28 May 2021 | +11.8% |
| 4 Jun 2021 | +4.3% |
| 11 Jun 2021 | +11.3% |
| 18 Jun 2021 | +7.1% |
| 25 Jun 2021 | +0.4% |
| 2 Jul 2021 | +4.7% |
| 9 Jul 2021 | −7.5% |
| 16 Jul 2021 | −9.4% |
| 23 Jul 2021 | −16.0% |
| 30 Jul 2021 | −17.1% |
| 6 Aug 2021 | −22.1% |
| 13 Aug 2021 | −37.2% |
| 20 Aug 2021 | −40.7% |
| 27 Aug 2021 | −38.7% |
| 3 Sep 2021 | −31.2% |
| 9 Sep 2021 | −35.9% |
| 17 Sep 2021 | −33.9% |
| 24 Sep 2021 | −36.3% |
| 1 Oct 2021 | −39.1% |
| 8 Oct 2021 | −38.2% |
| 14 Oct 2021 | −40.2% |
| 22 Oct 2021 | −40.4% |
| 29 Oct 2021 | −35.2% |
| 4 Nov 2021 | −33.6% |
| 12 Nov 2021 | −20.4% |
| 18 Nov 2021 | −15.8% |
| 26 Nov 2021 | −8.1% |
| 3 Dec 2021 | −11.7% |
| 10 Dec 2021 | −7.2% |
| 17 Dec 2021 | −6.6% |
| 24 Dec 2021 | +1.7% |
| 31 Dec 2021 | +2.5% |
| 7 Jan 2022 | −0.6% |
| 14 Jan 2022 | −4.2% |
| 21 Jan 2022 | −4.3% |
| 28 Jan 2022 | −7.1% |
| 4 Feb 2022 | −2.1% |
| 11 Feb 2022 | +6.2% |
| 18 Feb 2022 | +6.6% |
| 25 Feb 2022 | −4.4% |
| 4 Mar 2022 | −3.1% |
| 11 Mar 2022 | −2.8% |
| 17 Mar 2022 | −6.1% |
| 25 Mar 2022 | +1.4% |
| 1 Apr 2022 | −7.7% |
| 8 Apr 2022 | −1.3% |
| 13 Apr 2022 | +2.1% |
| 22 Apr 2022 | +3.6% |
| 29 Apr 2022 | +0.4% |
| 6 May 2022 | −1.3% |
| 13 May 2022 | −10.1% |
| 20 May 2022 | −9.5% |
| 27 May 2022 | −13.0% |
| 3 Jun 2022 | −14.6% |
| 10 Jun 2022 | −13.7% |
| 17 Jun 2022 | −7.7% |
| 24 Jun 2022 | −17.6% |
| 1 Jul 2022 | −12.2% |
| 8 Jul 2022 | −12.1% |
| 15 Jul 2022 | −10.8% |
| 22 Jul 2022 | −13.6% |
| 29 Jul 2022 | −12.2% |
| 5 Aug 2022 | −12.6% |
| 12 Aug 2022 | −6.9% |
| 19 Aug 2022 | −7.6% |
| 26 Aug 2022 | −5.4% |
| 2 Sep 2022 | −6.8% |
| 9 Sep 2022 | −10.6% |
| 16 Sep 2022 | −13.9% |
| 23 Sep 2022 | −14.8% |
| 30 Sep 2022 | −13.0% |
| 7 Oct 2022 | −10.0% |
| 14 Oct 2022 | −13.8% |
| 21 Oct 2022 | −10.0% |
| 28 Oct 2022 | −8.5% |
| 4 Nov 2022 | −6.9% |
| 11 Nov 2022 | −20.9% |
| 18 Nov 2022 | −19.7% |
| 25 Nov 2022 | −19.4% |
| 2 Dec 2022 | −17.1% |
| 9 Dec 2022 | −18.5% |
| 16 Dec 2022 | −19.7% |
| 23 Dec 2022 | −15.3% |
| 30 Dec 2022 | −18.3% |
| 6 Jan 2023 | −19.7% |
| 13 Jan 2023 | −18.9% |
| 20 Jan 2023 | −17.0% |
| 27 Jan 2023 | −17.9% |
| 3 Feb 2023 | −23.3% |
| 10 Feb 2023 | −0.1% |
| 17 Feb 2023 | +4.4% |
| 24 Feb 2023 | +8.1% |
| 3 Mar 2023 | +5.3% |
| 10 Mar 2023 | +7.1% |
| 17 Mar 2023 | +15.9% |
| 24 Mar 2023 | +19.5% |
| 31 Mar 2023 | +24.0% |
| 6 Apr 2023 | +24.4% |
| 13 Apr 2023 | +32.6% |
| 21 Apr 2023 | +35.5% |
| 28 Apr 2023 | +45.9% |
| 5 May 2023 | +46.1% |
| 12 May 2023 | +26.9% |
| 19 May 2023 | +22.0% |
| 26 May 2023 | +23.7% |
| 2 Jun 2023 | +37.0% |
| 9 Jun 2023 | +39.4% |
| 16 Jun 2023 | +30.7% |
| 23 Jun 2023 | +27.6% |
| 30 Jun 2023 | +27.5% |
| 7 Jul 2023 | +27.1% |
| 14 Jul 2023 | +18.5% |
| 21 Jul 2023 | +18.7% |
| 28 Jul 2023 | +24.3% |
| 4 Aug 2023 | +29.9% |
| 11 Aug 2023 | +32.8% |
| 18 Aug 2023 | +36.6% |
| 25 Aug 2023 | +27.6% |
| 1 Sep 2023 | +16.6% |
| 8 Sep 2023 | +18.1% |
| 15 Sep 2023 | +22.5% |
| 22 Sep 2023 | +16.1% |
| 29 Sep 2023 | +20.5% |
| 6 Oct 2023 | +16.4% |
| 13 Oct 2023 | +20.8% |
| 20 Oct 2023 | +9.3% |
| 27 Oct 2023 | +3.2% |
| 3 Nov 2023 | +0.9% |
| 12 Nov 2023 | +11.1% |
| 17 Nov 2023 | +12.4% |
| 24 Nov 2023 | +19.8% |
| 1 Dec 2023 | +19.1% |
| 8 Dec 2023 | +11.6% |
| 15 Dec 2023 | +5.8% |
| 22 Dec 2023 | +12.7% |
| 29 Dec 2023 | +6.2% |
| 5 Jan 2024 | +11.5% |
| 12 Jan 2024 | +5.5% |
| 20 Jan 2024 | +18.1% |
| 25 Jan 2024 | +19.0% |
| 2 Feb 2024 | +7.8% |
| 9 Feb 2024 | −13.2% |
| 16 Feb 2024 | −11.9% |
| 23 Feb 2024 | −14.1% |
| 2 Mar 2024 | −8.2% |
| 7 Mar 2024 | −5.2% |
| 15 Mar 2024 | −6.0% |
| 22 Mar 2024 | −9.3% |
| 28 Mar 2024 | −3.8% |
| 5 Apr 2024 | −5.8% |
| 12 Apr 2024 | −5.6% |
| 19 Apr 2024 | −9.0% |
| 26 Apr 2024 | −9.2% |
| 3 May 2024 | +2.7% |
| 10 May 2024 | +9.9% |
| 18 May 2024 | +11.8% |
| 24 May 2024 | +12.6% |
| 31 May 2024 | +6.4% |
| 7 Jun 2024 | +13.0% |
| 14 Jun 2024 | +13.7% |
| 21 Jun 2024 | +10.5% |
| 28 Jun 2024 | −0.5% |
| 5 Jul 2024 | +5.0% |
| 12 Jul 2024 | +10.6% |
| 19 Jul 2024 | +10.3% |
| 26 Jul 2024 | +10.8% |
| 2 Aug 2024 | +14.4% |
| 9 Aug 2024 | +16.6% |
| 16 Aug 2024 | +15.5% |
| 23 Aug 2024 | +15.5% |
| 30 Aug 2024 | +19.9% |
| 6 Sep 2024 | +13.6% |
| 13 Sep 2024 | +16.8% |
| 20 Sep 2024 | +11.8% |
| 27 Sep 2024 | +16.6% |
| 4 Oct 2024 | +10.1% |
| 11 Oct 2024 | +10.5% |
| 18 Oct 2024 | +8.1% |
| 25 Oct 2024 | +6.4% |
| 1 Nov 2024 | −1.1% |
| 8 Nov 2024 | −7.2% |
| 14 Nov 2024 | −12.1% |
| 22 Nov 2024 | −15.4% |
| 29 Nov 2024 | −15.1% |
| 6 Dec 2024 | −18.2% |
| 13 Dec 2024 | −20.5% |
| 20 Dec 2024 | −9.3% |
| 27 Dec 2024 | −7.6% |
| 3 Jan 2025 | −6.5% |
| 10 Jan 2025 | −12.1% |
| 17 Jan 2025 | −12.5% |
| 24 Jan 2025 | −9.9% |
| 1 Feb 2025 | −13.0% |
| 7 Feb 2025 | −5.8% |
| 14 Feb 2025 | −3.4% |
| 21 Feb 2025 | −2.0% |
| 28 Feb 2025 | −3.8% |
| 7 Mar 2025 | +0.4% |
| 13 Mar 2025 | +4.2% |
| 21 Mar 2025 | +1.4% |
| 28 Mar 2025 | −3.7% |
| 4 Apr 2025 | −7.8% |
| 11 Apr 2025 | −5.0% |
| 17 Apr 2025 | −0.6% |
| 25 Apr 2025 | −1.8% |
| 2 May 2025 | +4.1% |
| 9 May 2025 | −2.4% |
| 16 May 2025 | −4.7% |
| 23 May 2025 | −2.8% |
| 30 May 2025 | −6.2% |
| 6 Jun 2025 | −7.5% |
| 13 Jun 2025 | −8.5% |
| 20 Jun 2025 | −16.9% |
| 27 Jun 2025 | −14.1% |
| 4 Jul 2025 | −5.5% |
| 11 Jul 2025 | −8.3% |
| 18 Jul 2025 | −10.1% |
| 25 Jul 2025 | −13.3% |
| 1 Aug 2025 | −13.9% |
| 8 Aug 2025 | −14.0% |
| 14 Aug 2025 | −9.0% |
| 22 Aug 2025 | −13.2% |
| 29 Aug 2025 | −9.0% |
| 5 Sep 2025 | −8.6% |
| 12 Sep 2025 | −6.1% |
| 19 Sep 2025 | +0.1% |
| 26 Sep 2025 | +1.1% |
| 3 Oct 2025 | −6.0% |
| 10 Oct 2025 | +0.3% |
| 17 Oct 2025 | −4.8% |
| 24 Oct 2025 | −6.3% |
| 31 Oct 2025 | +0.9% |
| 7 Nov 2025 | +3.0% |
| 14 Nov 2025 | +7.7% |
| 21 Nov 2025 | +11.3% |
| 28 Nov 2025 | +12.8% |
| 5 Dec 2025 | +12.2% |
| 12 Dec 2025 | +6.9% |
| 19 Dec 2025 | +8.6% |
| 26 Dec 2025 | +6.0% |
| 2 Jan 2026 | +6.5% |
| 9 Jan 2026 | +5.5% |
| 16 Jan 2026 | +7.0% |
| 23 Jan 2026 | +8.5% |
| 1 Feb 2026 | +5.6% |
| 6 Feb 2026 | +6.4% |
| 13 Feb 2026 | −4.1% |
| 20 Feb 2026 | −2.2% |
| 27 Feb 2026 | +2.7% |
| 6 Mar 2026 | +6.9% |
| 13 Mar 2026 | +18.3% |
| 20 Mar 2026 | +15.3% |
| 27 Mar 2026 | +20.6% |
| 2 Apr 2026 | +22.8% |
| 10 Apr 2026 | +17.3% |
| 17 Apr 2026 | +20.8% |
| 24 Apr 2026 | +25.4% |
| 30 Apr 2026 | +20.3% |
| 8 May 2026 | +26.2% |
| 15 May 2026 | +35.3% |
| 22 May 2026 | +29.5% |
| 29 May 2026 | +19.1% |
| 4 Jun 2026 | +18.9% |
| 5 Jun 2026 | +7.8% |
| 9 Jun 2026 | +6.2% |
| 10 Jun 2026 | +3.1% |
| 12 Jun 2026 | +2.5% |
| 17 Jun 2026 | +1.8% |
| 19 Jun 2026 | +6.9% |
| 24 Jun 2026 | +5.9% |
| 25 Jun 2026 | +10.0% |
| 1 Jul 2026 | +3.6% |
| 3 Jul 2026 | +3.8% |
| 10 Jul 2026 | +3.8% |
| 17 Jul 2026 | +4.5% |
| 24 Jul 2026 | +2.7% |
| 31 Jul 2026 | +3.6% |
| 7 Aug 2026 | +9.5% |
| 14 Aug 2026 | +7.2% |
| 21 Aug 2026 | +6.0% |
| 28 Aug 2026 | +14.0% |
| 4 Sep 2026 | +9.9% |
| 11 Sep 2026 | +10.8% |
| 18 Sep 2026 | +12.7% |
| 25 Sep 2026 | +13.3% |
| 28 Sep 2026 | +7.8% |
| 1 Oct 2026 | +13.5% |
| 9 Oct 2026 | +16.7% |
| 16 Oct 2026 | +11.6% |
| 23 Oct 2026 | +8.1% |
| 30 Oct 2026 | +9.1% |
| 6 Nov 2026 | +11.6% |
| 8 Nov 2026 | +11.6% |
| 13 Nov 2026 | +9.9% |
| 18 Nov 2026 | +6.6% |
Over the last 11 years the share price moved +145% while the NIFTY 500 moved +279%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at Aurobindo Pharma this quarter?
Three changes stood out: revenue up on a year earlier for 13 quarters in a row (every quarter we can compare), foreign funds (FIIs) raised their stake for 3 quarters in a row and indian funds and insurers (DIIs) cut their stake for 3 quarters in a row.
Revenue up on a year earlier for 13 quarters in a row (every quarter we can compare)
In the September 2026 quarter revenue was ₹10,263 crore, +23.9% on a year earlier.
Why: Revenue rose because the US generics business sold more.
Next results: check whether the partnered inhaler gets a full quarter of sales and whether the company starts making its own metered dose inhaler.
From the earnings call on 5 Nov 2026.
Foreign funds (FIIs) raised their stake for 3 quarters in a row
From 14% to 17.4% of the company by the September 2026 quarter.
Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row
From 27.7% to 24.4% of the company by the September 2026 quarter.
What are Aurobindo Pharma's latest quarterly results?
For July to September 2026 (the quarter ended 30 September 2026), Aurobindo Pharma reported revenue of ₹10,263 crore, up 23.9% from ₹8,286 crore a year earlier, and a profit of ₹1,124 crore, up 32.5% from ₹848 crore.
Aurobindo Pharma results: July to September 2026 against a year earlier
| Measure | July to September 2026 | July to September 2025 | Change |
|---|---|---|---|
| Revenue | ₹10,263 crore | ₹8,286 crore | +23.9% |
| Profit | ₹1,124 crore | ₹848 crore | +32.5% |
| Earnings per share | ₹19.57 | ₹14.61 | +33.9% |
| Operating margin | 21.0% | 20.3% | +0.7 points |
The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).
Aurobindo Pharma's management discussed these results on a call held on 5 November 2026; what it said is further down this page.
From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.
What is the Aurobindo Pharma share price history?
Aurobindo Pharma closed at ₹1,796.30 on 18 November 2026, up 49.0% from ₹1,205.90 a year earlier (21 November 2025) and up 180.9% over five years. Its highest weekly close since March 2016 was ₹1,823.20 on 13 November 2026.
Aurobindo Pharma share price: then and now
| When | Close | Change to 18 Nov 2026 |
|---|---|---|
| 1 week ago · 11 Nov 2026 | ₹1,827.50 | −1.7% |
| 1 month ago · 19 Oct 2026 | ₹1,621.40 | +10.8% |
| 6 months ago · 15 May 2026 | ₹1,511.80 | +18.8% |
| 1 year ago · 21 Nov 2025 | ₹1,205.90 | +49.0% |
| 3 years ago · 17 Nov 2023 | ₹1,007.35 | +78.3% |
| 5 years ago · 18 Nov 2021 | ₹639.55 | +180.9% |
| 10 years ago · 18 Nov 2016 | ₹722.40 | +148.7% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹732.45 | +145.2% |
| Highest weekly close since March 2016, also the 52-week high · 13 Nov 2026 | ₹1,823.20 | −1.5% |
| Lowest weekly close since March 2016 · 20 Mar 2020 | ₹346.70 | +418.1% |
| 52-week low (weekly close) · 23 Jan 2026 | ₹1,132.50 | +58.6% |
Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
567 weekly closes from 11 March 2016 to 18 November 2026.
What is the latest news on Aurobindo Pharma?
18 Nov 2026: Aurobindo Pharma closed at ₹1,796.30, down 1.7% on the week and up 10.8% on the month. 11 Nov 2026: ex-date for an interim dividend of ₹7 a share.
Earlier
- 5 Nov 2026: Aurobindo Pharma held its results call for July to September 2026. Management guided: Long-term operating margin to 22% in coming years via Lannett yields and utilisation plus China and biosimilars-biologics levers.
- Results for July to September 2026: Revenue up 23.9% and profit up 32.5% on a year earlier.
What dividend does Aurobindo Pharma pay?
Aurobindo Pharma paid ₹7 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.39% at the ₹1,796.30 close on 18 November 2026. The last was an interim dividend of ₹7 a share, ex-date 11 November 2026.
Aurobindo Pharma dividends since 1 April 2021
| Ex-date | Dividend per share | Type | Record date |
|---|---|---|---|
| 11 Nov 2026Interim | ₹7 | Interim | same day |
| 8 Aug 2025Interim | ₹4 | Interim | same day |
| 20 Feb 2024Interim | ₹1.50 | Interim | same day |
| 20 Nov 2023Interim | ₹3 | Interim | same day |
| 17 Feb 2023Interim | ₹3 | Interim | same day |
| 6 Jun 2022Interim | ₹4.50 | Interim | 7 Jun 2022 |
| 18 Feb 2022Interim | ₹1.50 | Interim | 21 Feb 2022 |
| 17 Nov 2021Interim | ₹1.50 | Interim | 18 Nov 2021 |
| 27 Aug 2021Interim | ₹1.50 | Interim | 30 Aug 2021 |
Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date.
Yes. Aurobindo Pharma Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years.
From the exchange corporate-actions record, read 18 November 2026.
What did Aurobindo Pharma management say on the latest results call?
On the call for July to September 2026, held on 5 November 2026, Aurobindo Pharma's management guided: Long-term operating margin to 22% in coming years via Lannett yields and utilisation plus China and biosimilars-biologics levers.
“By Aurobindo's standard, Lannett is doing well. Overall, whatever EBITDA we have, Lannett is very close to it, that is what I would say.”Swami Iyer, on the call for July to September 2026
What management guided
- China oral solid dosage break-even this quarter on expanding international supplies and customer conversion.
- Operating cost base around ₹2,450 crore going forward with organic capital spending around $50 million per quarter for around $200 million yearly run-rate.
- Europe sustained double-digit growth with Eugia double-digit quarterly growth and mix toward 50:50 US and rest-of-world by FY28-29.
- Inhalation scale-up with Advair full benefit from next quarter and Raleigh lift in 6-9 months toward scaled 3-4 product portfolio by mid-2029.
Management’s own plans and goals, from our notes of the call. A plan is not a result.
Source: the call transcript.
From the call for July to September 2026, 5 November 2026.
What to watch in Aurobindo Pharma's next results?
When Aurobindo Pharma reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: China oral solid dosage to reach break-even this quarter - check loss reversal and supply momentum.
Management raised each of these on the latest results call.
- China oral solid dosage to reach break-even this quarter - check loss reversal and supply momentum.
- Partnered inhaler full-quarter flow-through plus in-house metered-dose manufacturing start - verify United States benefit and Raleigh utilisation lift.
- Pen-G scale-up toward next-year goal with price flow-through and anti-dumping progress - confirm operating leverage lift excluding incentive.
Which stock lists is Aurobindo Pharma on?
Aurobindo Pharma is on 5 of our India lists: Multibagger study list, Momentum stocks, 52 week high & low, Small & mid cap stocks and Pharma stocks.
Is Aurobindo Pharma profitable?
Aurobindo Pharma Ltd earned ₹1,124 Cr of net profit in the Sep 2026 quarter, +32.5% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY26 profit was ₹3,503 Cr. Over 10 years profit has grown 5.6% a year on average. The same quarter a year earlier earned ₹848 Cr.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
The Sep 2026 quarter's profit is 11.0% of that quarter's revenue.
For the full year, FY26 profit was ₹3,503 Cr (+0.5% on the year before).
Why profit moved: revenue changed +23.9% on a year earlier and the margin moved +0.7 percentage points. Sales did the work, and the margin was about flat.
On average over the last four quarters, profit changed +16.8% and revenue +13.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.
How much revenue does Aurobindo Pharma make, and is it growing?
Aurobindo Pharma Ltd reported ₹10,263 Cr of revenue in the Sep 2026 quarter, +23.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 9.3% a year on average. The last full year, FY26, came in at ₹33,653 Cr.
Revenue is everything the company billed its customers in the period.
The last four reported quarters add to ₹36,912 Cr.
FY26 revenue was ₹33,653 Cr, +6.1% on the year before.
Recent pace: the last four quarters grew +13.6% on average, against 9.3% a year over the longer run, so this year is growing faster than its own long-run rate.
Is growth speeding up? Revenue over the last 12 months grew +13.5%, against +10.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +16.5%, against +5.5% a year (accelerating).
How much of every ₹100 of sales does Aurobindo Pharma keep?
Aurobindo Pharma Ltd's operating margin was 21.0% in the Sep 2026 quarter, 0.7 percentage points higher than the same quarter a year ago. Across 13 years it has been between 14.9% and 26.4%. The latest quarter is within that range.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Why this happened. This is the capex inflection point: the money has been spent (five-year capex ₹17,506 Cr, capital work in progress ₹5,214 Cr) and ROCE is at 13%. As loss-making subsidiaries turn, two levers move together, EBITDA recovers the ₹200 Cr drag, and the effective tax rate falls from 31.9% toward the guided 28 to 29% because profits stop sitting in units with no tax credit. The model fails if the capacity lands into oversupplied markets: China profitability guidance was already cut to "positive".
Why the margin moved: operating margin changed +0.7 percentage points on the year while gross margin changed +1.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged.
Watch next
- Metric
- New platforms move from losses to contribution
- Threshold
- Effective tax rate stays above 31% through Q3 FY27, showing the loss-making units have not turned.
- Which result
- the next result
Is Aurobindo Pharma's profit turning into cash?
Over the last 3 years, 117% of Aurobindo Pharma Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹5,526 Cr of operating cash against ₹3,503 Cr of profit. After ₹2,686 Cr of spending on assets, ₹2,840 Cr was left over as free cash.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 117% of profit came in as cash: the cash cycle got 30 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.
What to look at next: the bigger use of cash is spending on new assets, at 1.5× depreciation over three years. The next section checks what that spending is building.
Where does Aurobindo Pharma's cash go?
Aurobindo Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 252 days in FY26, down from 282 days in FY21. It spent ₹7,434 Cr on assets over the last 3 years. Customers take 77 days to pay, and stock sits for 326 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
At FY26 sales of ₹33,653 Cr, each day of that cycle ties up about ₹92.2 Cr, so roughly ₹23,234 Cr is tied up in the business at any time.
FY26: customers took 77 days to pay and stock sat for 326 days, about 10.7 months of sales sitting as stock, for a full cycle of 252 days, shorter than FY21's 282.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 326 days. Customers pay about 77 days after that. Suppliers are paid at 151 days. Together that makes the 252-day cycle.
Spending on assets: ₹7,434 Cr over the last 3 years, against ₹4,949 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹5,214 Cr (FY26): assets paid for that are not earning yet.
In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.
What is Aurobindo Pharma's P/E ratio, and how does it compare with its own history?
Aurobindo Pharma Ltd's P/E is 26.0×, near the high end of its own history: higher than 97% of past readings. Its usual P/E (the middle reading) is 17.9×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
Why this happened. About $300M of annual US revenue at about 40% plant utilization; management will not guide on margin parity.
The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹69.05.
Why the multiple is where it is: over the past year earnings per share moved +17.0% while the price moved +49.0%. The price did better than earnings, which pushed the multiple up within its own range.
Where the price move came from: over 3 years the price moved +21.3% a year; about +20.3% a year came from earnings growth and about +1.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.
In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.
Watch next
- Metric
- Lannett acquisition, US scale and spare capacity
- Threshold
- Group operating margin falls below 20% in the first full Lannett quarters, showing the dilution is not being worked down.
- Which result
- the next result
What growth does the Aurobindo Pharma share price assume?
Worked out from its price on 11 October 2026, Aurobindo Pharma Ltd's share price assumed profit growth of about 17.0% a year. Over the past 10 years its profit actually grew 5.6% a year. Today its P/E is 26.0×, higher than 97% of its own last 11 years.
This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.
This is a one-day reading, taken on 11 October 2026. Every other number on this page, the multiple included, uses the latest price as of 18 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.
Is the Aurobindo Pharma business getting better or worse?
Aurobindo Pharma Ltd's business is turning around. Profit growth has swung from −3.6% at its recent low to +16.5%, improving for 4 quarters in a row, with ROCE steady at 13.7% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +6.1% | +10.6% | +6.3% | +9.3% |
| Profit | +0.5% | +22.0% | −8.1% | +5.6% |
| EPS | +0.5% | +22.4% | −7.9% | +5.7% |
| Share price | +49.0% | +21.3% | +22.9% | +9.5% |
What is the Aurobindo Pharma story, and has it been checked?
Aurobindo Pharma Ltd's story is not scored yet against the checks our research set on 10 October 2026. Where it sits in its own cycle: mid expansion.
NOT YET CHECKED
From the price. Price stage 2, week 49, above its 200-day line, relative strength falling.
Where they disagree. Earnings are only now starting to move (Q1 FY27 PAT +25%, about 16% on a core basis). Foreign shareholders have returned as customers in the last two quarters after a three-year rotation into domestic funds.
What is not proven yet. Conversely, two more quarters of core PAT growth above 15% with China and Pen-G both reported profitable would show the premium is being earned.
The test written in advance. Guidance credibility, platform timelines keep slipping. Measured by: Guidance credibility, platform timelines keep slipping China and Pen-G reported EBITDA-positive in the Q2 FY27 call; no new timeline slips by the next result.
What the company does. Q1 FY27 broke the flat run, revenue +16.3%, PAT +25.2%, but about 38% of the PAT gain was a doubling of other income; core growth was about 16%. FY27 guidance (EBITDA ₹8,000 Cr+, margin above 21%, tax down to 28 to 29%) implies EPS +17 to 26%; management has slipped seven of nine dated platform promises in a year.
The key numbers to watch, and the level that would change the picture
| Measure | Now | Why it matters | What to watch |
|---|---|---|---|
| Europe scale-up with captive and China… | HIGH | Europe crossed €1 billion in FY26 and grew 27 to 30% in the second half, at a 20% EBITDA margin; Q1 FY27 slowed to +11% in constant… | Europe constant-currency growth drops below 8% for two quarters or Europe EBITDA margin falls under 18%. |
| Pen-G / | MEDIUM | Captive 6-APA replaces imports: gross margin +153 bps YoY in Q1 FY27 and the plant turned EBITDA-positive in Q4 FY26 with ₹100+… | Gross margin slips back under 59% or the plant reports losses again because Chinese 6-APA pricing undercuts captive cost. |
| New platforms move from losses to… | HIGH | About ₹200 Cr of FY26 EBITDA losses in Pen-G, China and new ventures; turning them to breakeven alone lifts EBITDA about 3% and… | Effective tax rate stays above 31% through Q3 FY27, showing the loss-making units have not turned. |
| Lannett acquisition, US scale and spare… | MEDIUM | About $300M of annual US revenue at about 40% plant utilization; management will not guide on margin parity. | Group operating margin falls below 20% in the first full Lannett quarters, showing the dilution is not being worked down. |
| Growth markets and ARV momentum | LOW | Growth markets revenue +38% YoY in Q1 FY27 to ₹1,063 Cr, broad-based across countries. | Growth markets growth falls back under 10% YoY. |
| Biosimilars and contract biologics… | LOW | A generic-to-specialty move, but inflection is now 2030 and TheraNym revenue starts 2028, no contribution inside 12 months. | The first US biosimilar submissions slip out of calendar 2026. |
Everything further down this page is evidence for or against these.
FY26-Q2FY27-Q1
What the surface reading misses. The research reads it further: This is not a trough-margin artifact.
What the surface reading misses. The surface reading is: ROCE 13% at the 10th percentile of its own history, a weaker business than it was. The research reads it further: The denominator ballooned ahead of the numerator. Fixed assets rose from ₹9,374 Cr (FY21) to ₹17,407 Cr (FY26) with another ₹5,214 Cr in capital work in progress, and five-year capex of ₹17,506 Cr absorbed 91% of operating cash. Much of that capital sits in platforms that are still loss-making or pre-revenue (Pen-G, China plant, biosimilars, TheraNym Unit 1 with revenue only from 2028). So low ROCE is part gestation, part a genuinely lower-return generic base after Revlimid exits.
- 1 · Operating leveragebuilding
- 2 · Value-added mixbuilding
- 3 · Management changebuilding
- 4 · Paying down debtbuilding
- 5 · Regulatory approvalquiet
- 6 · Order-book winsquiet
- 7 · Consolidationquiet
- 8 · Demerger or value unlockbuilding
- 9 · Buybackquiet
- 10 · New geographiesquiet
- 11 · More business from existing customersquiet
- 12 · New product launchquiet
- 13 · Mandatory normsquiet
- 14 · A bigger market to servequiet
- 15 · Market-share gainsquiet
- 16 · Asset qualityquiet
Lever 4 · Paying down debt: building. Europe crossed €1 billion in FY26 and grew 27 to 30% in the second half, at a 20% EBITDA margin; Q1 FY27 slowed to +11% in constant currency. What proves it keeps working: Europe scale-up with captive and China supply. It stops working if Europe constant-currency growth drops below 8% for two quarters or Europe EBITDA margin falls under 18%.
Lever 3 · Management change: building. Captive 6-APA replaces imports: gross margin +153 bps YoY in Q1 FY27 and the plant turned EBITDA-positive in Q4 FY26 with ₹100+ Cr external sales. What proves it keeps working: Pen-G / 6-APA backward integration. It stops working if Gross margin slips back under 59% or the plant reports losses again because Chinese 6-APA pricing undercuts captive cost.
Lever 1 · Operating leverage: building. About ₹200 Cr of FY26 EBITDA losses in Pen-G, China and new ventures; turning them to breakeven alone lifts EBITDA about 3% and cuts the tax rate. What proves it keeps working: New platforms move from losses to contribution. It stops working if Effective tax rate stays above 31% through Q3 FY27, showing the loss-making units have not turned.
Lever 8 · Demerger or value unlock: building. About $300M of annual US revenue at about 40% plant utilization; management will not guide on margin parity. What proves it keeps working: Lannett acquisition, US scale and spare capacity. It stops working if Group operating margin falls below 20% in the first full Lannett quarters, showing the dilution is not being worked down.
Sources: our stock research file (10 October 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
The whole page in one table. Each row links to its section.
Did Aurobindo Pharma management deliver what it promised?
What Aurobindo Pharma Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Eugia FY27 Growth Outlook Not Reconciled · 5 November 2026. In Aug 2026, management explicitly guided Eugia to single-digit FY27 growth because of limited approvals and remediation work at Unit III. In Nov 2026, management described double-digit growth every quarter and full production capacity while also stating that prior guidance remained on track, without reconciling the materially different growth outlook.
Eugia FY27 Growth Outlook Reversed · 6 August 2026. In the May 2026 call, management expected the base Eugia business to continue growing at a double-digit rate. In the August 2026 call, management revised this to single-digit growth because of limited new approvals and Unit 3 remediation; although a reason was provided, the revision was not reconciled with the prior outlook.
China EBITDA Outlook Softened · 6 August 2026. In May 2026, management said China would contribute significantly in FY27 and that it was working toward a low double-digit EBITDA margin. In August 2026, management only said China should be positive, materially lowering the stated profitability expectation without explaining the change.
Pen-G MIP and PLI Benefits Became Conditional · 6 August 2026. Earlier calls described the Pen-G minimum import price as an issued government policy and expressed confidence that the PLI payment would be received. In August 2026, management said it had not achieved the MIP or relevant status and treated both MIP and PLI as conditional, creating material uncertainty around benefits that had previously supported the Pen-G profitability outlook.
Every quote above is taken word for word from the company’s own earnings calls.
What is Aurobindo Pharma management's track record?
Named promoters' challenge to SEBI's profit-deposit directive was dismissed by the High Court. The company says there is no operating or financial impact, which does not exempt promoter conduct under the management rule. The separate old liquor case is reported acquitted and is not used as a veto.
Checked 14 October 2026.
How much does Aurobindo Pharma earn on its capital?
Aurobindo Pharma Ltd earned a ROCE of 13% in FY26. That is up from a low of 9% in FY23. Its return on capital used (ROIC) is 1.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
It comes from a 10.4% net margin and 0.58× asset turnover (sales divided by assets).
Why the return is what it is (FY26): a 10.4% net margin × 0.58× asset turnover × 1.54× leverage (assets divided by equity) ≈ 9.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.
The key test, return on capital used minus the cost of capital: 10.7% − 12.0% = −1.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.
Does Aurobindo Pharma have too much debt?
Aurobindo Pharma Ltd has total debt of ₹8,630 Cr against shareholder equity of ₹39,400 Cr as of Sep 2026, so its debt is 0.22× its equity, which is very little. Year by year, that ratio went from 0.12 in FY22 to 0.21 in FY26. So the returns on this page come from the business, not from borrowed money.
Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.
Why this happened. Europe is the largest growth engine. Revenue grew 27% in Q3 FY26 and 30% in Q4 FY26, with EBITDA at 20% and management citing captive supply and lower third-party dependence. Q1 FY27 slowed to 11% in constant currency, consistent with the double-digit floor management guided for FY27. Second-order: the China tablet plant and in-house sourcing are the cost lever that keeps tender pricing profitable; competitors without captive supply bear the solvent and freight inflation management flagged. The remaining benefit is margin, not growth rate.
Watch next
- Metric
- Europe scale-up with captive and China supply
- Threshold
- Europe constant-currency growth drops below 8% for two quarters or Europe EBITDA margin falls under 18%.
- Which result
- the next result
What is the Aurobindo Pharma shareholding pattern?
No group of Aurobindo Pharma Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved −0.8 points over the same period, to 24.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
Why this happened. Captive 6-APA replaces imports: gross margin +153 bps YoY in Q1 FY27 and the plant turned EBITDA-positive in Q4 FY26 with ₹100+ Cr external sales.
Over the last two years: Foreign institutions: +0.8 points over 8 quarters, to 17.4%; Domestic institutions: −0.8 points over 8 quarters, to 24.4%; Promoters: +0.1 points over 8 quarters, to 51.9%.
Watch next
- Metric
- Pen-G / 6-APA backward integration
- Threshold
- Gross margin slips back under 59% or the plant reports losses again because Chinese 6-APA pricing undercuts captive cost.
- Which result
- the next result
How far is Aurobindo Pharma from balance-sheet trouble?
For Aurobindo Pharma Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
How does Aurobindo Pharma rank in its industry?
58.9 out of 100, rank 13 of 44 in Pharma - Formulators, with 100% of the evidence available.
Aurobindo Pharma Ltd scores 58.9 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 13. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
The four parts add up to the total exactly: 18.9 + 13.3 + 10.6 + 16.1 = 58.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Aurobindo Pharma compared with?
Aurobindo Pharma ranks 13 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 58.9 out of 100.
- 1Marksans Pharma LtdMARKSANS · losing its lead · Most evidence points up · 78% evidence75.8out of 100
How the score adds up
Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidenceCapital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidenceValuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks aheadExact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Emcure Pharmaceuticals LtdEMCURE · leader · Most evidence points up · 75% evidence72.8out of 100
How the score adds up
Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidenceCapital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidenceValuation 10.0/20 · P/E 40.5× · PEG — · 15% evidenceRelative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks aheadExact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 3Kwality Pharmaceuticals LtdKPL · breaking out · Most evidence points up · 75% evidence68.3out of 100
How the score adds up
Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidenceCapital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidenceValuation 6.5/20 · P/E 45.5× · PEG — · 50% evidenceRelative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks aheadExact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 4Rubicon Research LtdRUBICON · losing its lead · Most evidence points up · 87% evidence67.4out of 100
How the score adds up
Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidenceCapital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidenceValuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidenceRelative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks aheadExact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 5Accent Microcell LtdACCENTMIC · losing its lead · Most evidence points up · 65% evidence66.2out of 100
How the score adds up
Growth & earnings 21.8/35 · Revenue — · Profit — · Operating margin change 7 points · 27% evidenceCapital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidenceValuation 10.1/20 · P/E 25.6× · PEG — · 50% evidenceRelative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks aheadExact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 6Ajanta Pharma LtdAJANTPHARM · quiet · Most evidence points up · 100% evidence65.7out of 100
How the score adds up
Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidenceCapital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidenceValuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidenceRelative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks aheadExact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. - 7Mankind Pharma LtdMANKIND · turning · Most evidence points up · 100% evidence65.3out of 100
How the score adds up
Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidenceCapital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidenceValuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidenceRelative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks aheadExact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 8Bliss GVS Pharma LtdBLISSGVS · leader · Most evidence points up · 82% evidence65.3out of 100
How the score adds up
Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidenceCapital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidenceValuation 6.5/20 · P/E 44.8× · PEG — · 50% evidenceRelative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 9Alembic Pharmaceuticals LtdAPLLTD · leader · Evidence leans up · 85% evidence64.0out of 100
How the score adds up
Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidenceCapital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidenceValuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidenceRelative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks aheadExact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 10Ipca Laboratories LtdIPCALAB · leader · Evidence leans up · 82% evidence62.4out of 100
How the score adds up
Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidenceCapital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 11.7/20 · P/E 33.5× · PEG — · 50% evidenceRelative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Fredun Pharmaceuticals LtdFREDUN · losing its lead · Evidence leans up · 70% evidence61.2out of 100
- 12FDC LtdFDC · turning · Evidence leans up · 75% evidence59.2out of 100
- 13Aurobindo Pharma Ltd this pageAUROPHARMA · leader · Evidence leans up · 100% evidence58.9out of 100
How the score adds up
Growth & earnings 18.9/35 · Revenue 13.5% · Profit 16.5% · Operating margin change 1 points · 100% evidenceCapital efficiency 13.3/25 · ROCE 12.9% (year to Mar 2026) · Operating margin 21% · 100% evidenceValuation 10.6/20 · P/E 26× · PEG 1.27 · 100% evidenceRelative strength 16.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 7.5% · Strength vs NIFTY 500 (same reading) 22.1% · 1 year 49% · 100% evidence · 12 of 12 weeks aheadExact sum: 18.9 + 13.3 + 10.6 + 16.1 = 58.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 14Corona Remedies LtdCORONA · breaking out · Evidence leans up · 73% evidence58.3out of 100
- 15Lupin LtdLUPIN · quiet · Evidence leans up · 90% evidence57.2out of 100
- 16Gufic BioSciences LtdGUFICBIO · leader · Evidence leans up · 75% evidence56.8out of 100
- 17ERIS Lifesciences LtdERIS · basing · Evidence leans up · 67% evidence56.0out of 100
- 18Kilitch Drugs (India) LtdKILITCH · turning · Evidence leans up · 82% evidence55.8out of 100
- 19Caplin Point Laboratories LtdCAPLIPOINT · quiet · Evidence leans up · 90% evidence55.2out of 100
- 20Wockhardt LtdWOCKPHARMA · losing its lead · Evidence leans up · 83% evidence54.7out of 100
- 21Influx Healthtech LtdINFLUX · quiet · Evidence leans up · 63% evidence54.3out of 100
- 22Amrutanjan Health Care LtdAMRUTANJAN · breaking out · Evidence leans up · 90% evidence54.1out of 100
- 23Akums Drugs & Pharmaceuticals LtdAKUMS · losing its lead · Evidence leans up · 75% evidence53.3out of 100
- 24Strides Pharma Science LtdSTAR · breaking out · Evidence leans up · 82% evidence52.3out of 100
- 25Zydus Lifesciences LtdZYDUSLIFE · breaking out · Evidence leans up · 90% evidence51.5out of 100
- 26Glenmark Pharmaceuticals LtdGLENMARK · breaking out · Evidence leans up · 90% evidence50.6out of 100
- 27Bafna Pharmaceuticals LtdBAFNAPH · breaking out · Evidence leans down · 68% evidence49.1out of 100
- 28Alkem Laboratories LtdALKEM · quiet · Evidence leans down · 82% evidence48.3out of 100
- 29J B Chemicals & Pharmaceuticals LtdJBCHEPHARM · Too little evidence to rank firmly · 59% evidence45.8out of 100
- 30Bharat Parenterals LtdBPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence45.8out of 100
- 31Zim Laboratories LtdZIMLAB · leader · Evidence leans down · 74% evidence42.8out of 100
- 32Bajaj Healthcare LtdBAJAJHCARE · basing · Evidence leans down · 90% evidence42.7out of 100
- 33Lincoln Pharmaceuticals LtdLINCOLN · quiet · Evidence leans down · 90% evidence41.5out of 100
- 34Sun Pharmaceutical Industries LtdSUNPHARMA · quiet · Evidence leans down · 100% evidence39.8out of 100
- 35RPG Life Sciences LtdRPGLIFE · losing its lead · Evidence leans down · 90% evidence38.9out of 100
- 36Indoco Remedies LtdINDOCO · turning · Too little evidence to rank firmly · 52% evidence37.8out of 100
- 37Suven Life Sciences LtdSUVEN · quiet · Most evidence points down · 67% evidence34.4out of 100
- 38Torrent Pharmaceuticals LtdTORNTPHARM · quiet · Most evidence points down · 100% evidence34.2out of 100
- 39Natco Pharma LtdNATCOPHARM · quiet · Most evidence points down · 90% evidence31.9out of 100
- 40Dr Reddys Laboratories LtdDRREDDY · breaking out · Most evidence points down · 100% evidence30.4out of 100
- 41Cipla LtdCIPLA · quiet · Most evidence points down · 100% evidence27.9out of 100
- 42Biocon LtdBIOCON · basing · Most evidence points down · 100% evidence22.7out of 100
- 43Syncom Healthcare LtdSYNCOM · Too little evidence to rank firmly · 17% evidence42.4out of 100
- 44Sai Parenterals LtdSAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence38.3out of 100
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Pharma - Formulators, all 44 compared on one page.
Which companies are close to Aurobindo Pharma in size?
Aurobindo Pharma is the 7th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Dr Reddys Laboratories, Cipla and Mankind Pharma. Just below it: Lupin, Glenmark Pharmaceuticals and Alkem Laboratories.
Pharma - Formulators companies close in size
- Dr Reddys Laboratories Ltd ₹1,16,787 crore
- Cipla Ltd ₹1,14,478 crore
- Mankind Pharma Ltd ₹1,08,424 crore
- Aurobindo Pharma Ltd ₹1,03,355 crore
- Lupin Ltd ₹90,174 crore
- Glenmark Pharmaceuticals Ltd ₹74,679 crore
- Alkem Laboratories Ltd ₹62,443 crore
All 44 Pharma - Formulators companies, largest first
Companies close in size in other industries
- Hero MotoCorp Ltd ₹1,05,145 crore · Auto - 2 & 3 Wheelers
- United Spirits Ltd ₹1,04,811 crore · Alcoholic Beverages
- Aurobindo Pharma Ltd ₹1,03,355 crore
- Indus Towers Ltd ₹1,03,310 crore · Telecom Services
- FSN E-Commerce Ventures Ltd ₹1,00,837 crore · New age - Platform - E-Retail
What else do people ask about Aurobindo Pharma?
What is Aurobindo Pharma's share price today?
Aurobindo Pharma Ltd's share price is ₹1,796.30, +49.0% over the past year. The whole company is worth ₹1,03,367 Cr on the market.
In the last 52 weeks it traded between ₹1,133 to ₹1,823; today it is 96% of the way up from the low, 18.0% above its 200-day average (as of 18 November 2026).
What were Aurobindo Pharma's latest quarterly results?
Aurobindo Pharma Ltd reported revenue of ₹10,263 Cr and net profit of ₹1,124 Cr for the Sep 2026 quarter. Revenue rose 23.9% and profit rose 32.5% compared with a year earlier. Earnings per share were ₹19.57.
The operating margin was 21.0%, 0.7 percentage points higher than a year earlier (as of 18 November 2026).
What is Aurobindo Pharma's market cap?
Aurobindo Pharma Ltd's market capitalisation is ₹1,03,367 Cr at a share price of ₹1,796.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).
How is Aurobindo Pharma performing?
Aurobindo Pharma Ltd's share price has been rising for 49 weeks. In its latest quarter, revenue rose 23.9% and profit rose 32.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 47 weeks running (as of 18 November 2026).
Will Aurobindo Pharma's share price go up?
This page does not forecast Aurobindo Pharma Ltd's share price. What it shows instead: the share price is ₹1,796.30, and it has been rising for 49 weeks. Its P/E of 26.0× is higher than 97% of its own last 11 years (as of 18 November 2026).
Who owns Aurobindo Pharma?
Promoters own 51.9% of Aurobindo Pharma Ltd, foreign institutions 17.4%, domestic institutions 24.4%, the public 6.3% and the government 0.1% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 November 2026).
Where is Aurobindo Pharma in its business cycle?
Aurobindo Pharma Ltd's FY26 operating margin was 20.4%, against a 13-year range of 14.9% to 26.4%. The latest quarter was 21.0%, the middle of its own range, neither a peak nor a low.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).
What could break the Aurobindo Pharma story?
The main question: the share price moved +49.0% in a year while earnings per share (last four quarters) moved +17.0%. The difference came from the market paying a higher multiple.
On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).
Is Aurobindo Pharma a stock worth studying right now?
What the numbers show: Aurobindo Pharma Ltd's share price has risen faster than its earnings: +49.0% in a year, against +17.0% for earnings per share. The main open question: whether earnings grow into a price that has already moved.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).
Is there a Aurobindo Pharma share price forecast for 2026?
What management itself guided: Long-term operating margin to 22% in coming years via Lannett yields and utilisation plus China and biosimilars-biologics levers.
Where does this page get Aurobindo Pharma's management information?
From Aurobindo Pharma's results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results.
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.